PRVI POTVRĐENI SLUČAJ DELTA VARIJANTE SARS-COV-2 U SRBIJI
Ključne reči:
COVID-19; SARS-CoV-2; Delta varijanta.
Sažetak
Teški akutni respiratorni sindrom koronavirus 2 je beta-korona virus grupe 2B koji pripada porodici Coronaviridae. Delta varijanta, koja se pojavila u indijskoj državi Maharaštri u decembru 2020, danas je najzastupljenija varijanta i sastoji se od 3 podtipa, B.1.617.1, B.1.617.2, B.1.617.3. Brzina prenosa Delta varijante je 50% -60% veća od Alpha varijante i upravo ovaj tip korona virusa trenutno zabrinjava svetsku populaciju.
U ovom radu predstavljamo slučaj prvog registrovanog pacijenta sa Delta varijantom COVID-19 u Srbiji.
Reference
1. Lazarevic I, Pravica V, Miljanovic D, Cupic M. Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far? Viruses 2021; 13(7):1192. doi: 10.3390/v13071192.
2. Adil MT, Rahman R, Whitelaw D, et al. SARS-CoV-2 and the pandemic of COVID-19. Postgrad Med J 2021; 97(1144):110-116. doi: 10.1136/postgradmedj-2020-138386.
3. Salian VS, Wright JA, Vedell PT, et al. COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. Mol Pharm 2021; 18(3): 754-771. doi: 10.1021/acs.molpharmaceut.0c00608.
4. Edara VV, Pinsky BA, Suthar MS, et al. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N Engl J Med 2021; 385(7): 664-666. doi: 10.1056/NEJMc2107799.
5. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2021 Jul 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. PMID: 32150360.
6. Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill 2021; 26(24): 2100509. doi: 10.2807/1560-7917.ES.2021.26.24.2100509.
7. Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE. SARS-CoV-2 variants of concern are emerging in India. Nat Med 2021; 27(7):1131-1133. doi: 10.1038/s41591-021-01397-4.
8. Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status - New York, May 3-July 25, 2021. MMWR Morb Mortal Wkly Rep 2021; 70(34):1150-1155. doi: 10.15585/mmwr.mm7034e1.
9. Rao V, Arakeri G, Madikeri G, Shah A, S Oeppen R, A Brennan P. Post-COVID Mucormycosis in India: A formidable challenge. Br J Oral Maxillofac Surg 2021;doi:10.1016/j.bjoms.2021.06.013
10. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med 2021; 385(7): 585-594. doi: 10.1056/NEJMoa2108891.
2. Adil MT, Rahman R, Whitelaw D, et al. SARS-CoV-2 and the pandemic of COVID-19. Postgrad Med J 2021; 97(1144):110-116. doi: 10.1136/postgradmedj-2020-138386.
3. Salian VS, Wright JA, Vedell PT, et al. COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. Mol Pharm 2021; 18(3): 754-771. doi: 10.1021/acs.molpharmaceut.0c00608.
4. Edara VV, Pinsky BA, Suthar MS, et al. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N Engl J Med 2021; 385(7): 664-666. doi: 10.1056/NEJMc2107799.
5. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2021 Jul 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. PMID: 32150360.
6. Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill 2021; 26(24): 2100509. doi: 10.2807/1560-7917.ES.2021.26.24.2100509.
7. Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE. SARS-CoV-2 variants of concern are emerging in India. Nat Med 2021; 27(7):1131-1133. doi: 10.1038/s41591-021-01397-4.
8. Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status - New York, May 3-July 25, 2021. MMWR Morb Mortal Wkly Rep 2021; 70(34):1150-1155. doi: 10.15585/mmwr.mm7034e1.
9. Rao V, Arakeri G, Madikeri G, Shah A, S Oeppen R, A Brennan P. Post-COVID Mucormycosis in India: A formidable challenge. Br J Oral Maxillofac Surg 2021;doi:10.1016/j.bjoms.2021.06.013
10. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med 2021; 385(7): 585-594. doi: 10.1056/NEJMoa2108891.